Eupraxia Pharmaceuticals Stock

Detail Data
Volume (24h): 2,103 shares
P/E Ratio: /
Forward P/E: -11.23
EPS: -1.19 CAD
Forward EPS: -0.65 CAD
Number of Shares: 35,959,600 shares
Market Capitalization: 262,505,088.00 CAD

Dividend

Dividend Value
Dividend Amount According to our data, the company Eupraxia Pharmaceuticals does not currently pay dividends.
Annual Yield %: -
Ex-dividend Date: -
5-Year Avg Yield %: -
Payout Ratio: -
Last Dividend Value: -
Last Dividend Date: -

Analyst Forecast

Most analysts have issued a strong_buy recommendation for Eupraxia Pharmaceuticals stock. The current number of analysts covering this company is 3. The highest target price is 16.5 CAD, while the lowest target price is 9 CAD. The median target valuation set by analysts is 12 CAD. These forecasts and recommendations provide insight into how analysts view the future stock performance of Eupraxia Pharmaceuticals.
Analysts Recommendation
Issued Recommendation: According to our data, the recommendation for Eupraxia Pharmaceuticals stock is: strong_buy
Number of Analysts: 3
Highest Target Price: 16.5 CAD
Lowest Target Price: 9 CAD
Median Target Price: 12 CAD

Fundamental Indicators

Indicator Data
Total Revenue: /
Net Income: -29,381,364.00 CAD
Price-to-Book (P/B): /
PEG Ratio: /
Exchange: Toronto
Industry: Biotechnology
Sector: Healthcare
Number of Employees: 33
Country: Canada

Where to Buy Eupraxia Pharmaceuticals Stock?

You can purchase Eupraxia Pharmaceuticals stock on the Toronto under the ticker symbol: EPRX.TO. Several stock brokers or banks offer trading services for these stocks. Popular stock brokers like XTB and eToro allow you to buy real stocks and ETFs with zero or minimal commissions. Banks usually charge higher fees. Remember, investing in stocks involves risks, so it's important to carefully consider your financial situation and investment goals.

1

Real stocks and ETFs. Low minimum deposit, only 50 EUR. Option to copy trades. Advanced stock analysis and free education.

Trustpilot rating 4.4/5 Google play rating 4.2/5
Invest in Stocks with eToro
★★★★★ 5.0
2

Real stocks and ETFs + free demo account. Low fees + fast customer support. More than 5,200 instruments available for trading. Free training and education. Regular live streams on YouTube.

Trustpilot rating 3.6/5 Google play rating 4.5/5
Try Free Demo Account
★★★★☆ 4.8
Risk warning: Trading CFDs involves a high risk of financial loss. Between 51%-eToro -89% of retail investor accounts lose money when trading CFDs. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.

More Information on Eupraxia Pharmaceuticals Stock

Indicator Value
Company Revenue: -
EBITDA: -29,013,050.00 CAD - Negative EBITDA may signal financial challenges or growth investments.
Earnings Per Share: -1.19 CAD
Book Value Per Share: -0.26 CAD
Total Cash: 19,765,644.00 CAD
Total Cash per Share: 0.55 CAD
Total Debt: 35,065.00 CAD
Debt to Equity Ratio: 0.00
Quick Ratio 7.60
Current Ratio 8.72
Free Cash Flow -20,768,172.00 CAD
Operating Cash Flow -30,480,264.00 CAD
Gross Margins -
EBITDA Margins -
Operating Margins -
Profit Margins -
Return on Assets -75.0 %
Return on Equity -169.2 %
Earnings Growth (1 year) -
Revenue Growth (1 year) -
Quarterly Earnings Year-over-Year Growth -
Market Capitalization 262,505,088.00 CAD
Enterprise Value 269,306,272.00 CAD
EV/Revenue -
EV/EBITDA -9.282
Float Shares 24,992,619 shares
Shares Outstanding 35,959,600 shares
Held Percent Insiders 0.19 %
Held Percent Institutions 5.31 %
Shares Short 1,057
Shares Short Prior Month 612
Date Short Interest 2025-08-15
Short Percentage of Total Shares -
Short Ratio 0.05
Beta 1.54
Short Percentage of Float -
Implied Shares Outstanding 35,959,600

Frequently Asked Questions (FAQ)

According to our data, the company Eupraxia Pharmaceuticals does not pay dividends yet, even in 2025.

Eupraxia Pharmaceuticals shares are traded on the Toronto stock exchange under the ticker: EPRX.TO. You can buy or trade them through a variety of stock brokers who provide real stock trading services.

According to our data, the recommendation for Eupraxia Pharmaceuticals shares is from a total of 3 analysts. The average target price prediction is 12 CAD per share.

The total number of Eupraxia Pharmaceuticals shares on the exchange is 35,959,600.00 shares, which at the current market capitalization gives the company a total valuation of 262,505,088.00 CAD.